Increasing the Therapeutic Potential of Stem Cell Therapies for Critical Limb Ischemia

Hallie J Quiroz1, Samantha F Valencia2, Zhao-Jun Liu1,*, Omaida C Velazquez1,*

1Dewitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, USA
2University of Miami Miller School of Medicine, Miami, USA

Abstract
Peripheral Arterial Disease (PAD) is a progressive, atherosclerotic disease that at its end stage, Critical Limb Ischemia (CLI), results in severely diminished limb perfusion and causes leg pain at rest, non-healing ulcers, and tissue gangrene. Many patients with CLI fail current medical and surgical therapies and thus are deemed “no option” and require limb amputation. Novel therapies to attempt limb salvage in these “no option” patients are needed. Stem cell therapy is one therapeutic angiogenic avenue that has been tested over the last 20 years. To date, clinical trials have shown promise but with only modest improvement and none demonstrated a significant decrease in amputation rates in those treated with stem cell therapy. Thus, recent investigations into improving stem cell therapy have been the focus of our laboratory and many others. This review aims to describe recent advances in increasing the therapeutic potential of stem cell therapies for CLI.

Keywords
Critical limb ischemia; Stem cell therapy

3. Introduction
Peripheral Arterial Disease (PAD) is a progressive systemic atherosclerotic disease which results in the narrowing of peripheral arteries and progressively decreases extremity perfusion. The end-stage of PAD, Critical Limb Ischemia (CLI), is defined as patients with chronic ischemic rest pain, ulcers or gangrene attributable to PAD [1]. Current treatment options for PAD and CLI involve risk factor modification strategies such as smoking cessation, glycemic control (if concomitant Diabetes Mellitus), cholesterol reduction, and surgical revascularization procedures dependent upon patient specific anatomy. Unfortunately, roughly 11% of PAD patients will progress to CLI every year.
[2], and those with concomitant diabetes are 40 times more likely to develop CLI [3]. CLI patients have an exceedingly high 6-month mortality rate of ~20%, while another 40% require major amputation within one year of diagnosis [4]. Unfortunately, diabetic patients have a 20–30% prevalence of PAD [1,5], which is higher than that in non-diabetics and they are more likely to develop symptomatic PAD with eventual progression to CLI [6]. Diabetic patients also tend to develop multifocal disease with concomitant aberration in immune function and peripheral neuropathy, which results in poor wound healing and resultant higher amputation rates than their non-diabetic counterparts [7]. Patients who eventually require amputation despite medical therapies and surgical revascularization procedures are deemed “no-option” patients, because their disease is too advanced for current therapies to afford limb salvage. Thus, there remains an unmet need for vascular regenerative therapies to improve limb perfusion and functionality for these no-option patients to avoid amputations and potential death.

Therapeutic angiogenesis, the therapeutic development of new blood vessels, may offer novel vascular regenerative strategies for limb salvage. One such strategy includes Stem Cell Therapy (SCT), and over the last two decades has resulted in over 50 phase I/II clinical trials for patients with PAD [8]. Stem cells are appealing due to their inherent ability to self-renew, differentiate into multiple cell types, exert paracrine actions (such as induce angiogenesis), and have immunomodulatory effects [9]. Necessarily the term “stem cell” is broad because it encompasses the range of embryonic stem cells, with totipotent capacity, to the adult stem cells with more limited differentiation capabilities. Mesenchymal Stem Cells (MSC) of either bone-marrow derived origin or adipose tissue-derived are by far the most commonly utilized stem cells due to their known pro-angiogenic and pro-repair phenotypes with their combined abilities to differentiate into cells required for tissue repair and regeneration in an ischemic environment [9]. Although MSC have shown promise, other stem/progenitor cells such as autologous Endothelial Progenitor Cells (EPCs) and Hematopoietic Progenitor Cells (HPC), or allogeneic stem cells derived from extra-embryonic structures are being utilized in pre-clinical and clinical trials with increased frequency, denoting their importance in angiogenic therapies [8,10–14]. Despite two decades of investigations, there currently remains a lack of finalized Phase III cell therapy trials that have shown a clinically significant decrease in the amputation free survival for treatment groups [8]. Many have suggested that the modest clinical efficacy may be due to the inherent dysfunction of host cells [11,15–18]. This review will focus on recent advances in cell-based therapies that aim to improve upon a host’s dysfunctional cells or increase the cell’s inherent therapeutic angiogenic potential (Figure 1). This may be achieved by strategies including increasing host stem/progenitor cell mobilization or homing, improve cell delivery methods, engineer cells to augment angiogenesis, utilize stem cells from extra embryonic structures, or other novel methods.

4. Increase Stem/Progenitor Cell Mobilization and Tissue Homing

One strategy for enhancing the therapeutic potential of stem cells is to either increase the mobilization of endogenous stem/progenitor cells or to increase stem cell tissue homing capabilities (either endogenously or via exogenously injected cells) to afford a more robust involvement in the angiogenic processes occurring in the post-ischemic environment. The
augmentation of stem cell mobilization and homing as therapeutic strategies is enticing especially in patients that have been shown to have poor mobilization and homing of their stem/progenitor cells such as diabetic patients [19] and those with CLI [11]. Strategies have been described to augment their innate lack of mobilization [20]. Recently, new strategies have been developed to increase stem/progenitor cells in the circulatory system. Kwon et al. administered daily Intramuscular (IM) injections of Ac-PGP (N-acetyl Proline-Glycine-Proline, a collage-derived chemotactic tripeptide) to a murine model of hindlimb ischemia and evaluated the extent of progenitor cell mobilization (Sca1+Flk1+ cells) and the effects on ischemic limb reperfusion in a hindlimb ischemia model [21]. The same investigators had previously shown that this peptide, which is a byproduct of collagen breakdown by Matrix Metalloproteinase (MMP) and prolyl endopeptidases [22], was able to accelerate wound neovascularization and wound repair by promoting homing and engraftment of exogenous human Endothelial Progenitor Cells (EPCs) in the setting of tissue ischemia [23]. In their more recent work, IM injections of Ac-PGP improved limb reperfusion, and increased mobilization of progenitor cells [21]. Zhang et al., have also demonstrated a therapeutic increase in circulating EPCs and enhancement of their homing and angiogenic activity via the administration of recombinant growth differentiation factor-11 (rGDF11) [24]. GDF11 belongs to the Transforming Growth Factor-β (TGF-β) family and among many effects, has demonstrated protective effects against ischemic endothelial injury and atherosclerotic lesion formation [25]. Thus, Zhang et al., aimed to utilize rGDF11 to rescue EPCs from the inherent damage seen in the diabetic phenotype and have been able to demonstrate improvement in neovascularization in a rat model of diabetic limb ischemia. GDF11 restoration improved EPC mobilization and functionality, limb reperfusion, and even improved the metabolic characteristics of the diabetic rats.

Other technologies such as nanocarriers and nanodiscs have been employed to increase bone marrow mobilization and increase the homing potential of stem/progenitor cells such as MSC and EPC. Park et al. utilized nanodiscs to increase the in vivo stability of Substance P (SP), which is an endogenous peptide that is associated with bone marrow progenitor/stem cell mobilization [26] and induction of angiogenesis in a hindlimb ischemia model [27]. They did this by conjugating SP to HDL (high-density lipoprotein) nanodiscs, which they demonstrated had increased in vivo half-life and induced a more robust bone marrow mobilization response with increased therapeutic angiogenesis [28]. While this strategy focused on increasing endogenous stem cell mobilization, other investigations have focused on improving stem cell homing capabilities. Liu et al. have previously shown that E-selectin, an inducible cell-adhesion molecule, and its ligand are upregulated via Stromal-Derived Factor-1 (SDF-1α) in ischemic environments [29,30] and are required for successful neovascularization. MSC were then coated with acetylated-G5 dendrimers (Ac-G5) associated with E-selectin, known as Ac-G5-sE-sel nanocarriers. Compared to controls, these nanocarrier-coated MSCs injected systemically demonstrated superior tropism, homing, and potentiated angiogenesis and wound repair in an ischemic diabetic wound model [31]. Thus, technologies to increase stem cell mobilization and homing abilities are useful strategies that may ultimately prove useful to improve stem cell therapeutic angiogenesis (Table 1).
5. Increase Delivery Methods to Enhance Cell Survival, Engraftment, and Paracrine Effects

Another strategy for augmenting the therapeutic effects of stem/progenitor cell therapies is to engineer mechanisms to enhance the cell’s tissue viability. This is typically achieved by developing cell delivery vehicles that protect the cells in the microenvironment or engineering the cells via genetic modifications to enhance cell survival. Over the last couple of years, many investigators have been developing hydrogels to enhance the survival and effects of stem cells. Wang et al. developed a thermoresponsive Methyl-Cellulose (MC)-based hydrogel that allows for controlled release of placental MSC (P-MSC) over lower temperatures ($T_{gel} \approx 32^\circ C$) [32], temperature of ischemic tissues has been shown to be decreased in CLI patients with chronic wounds versus healthy controls [33]. Utilization of the thermoresponsive MC-hydrogel as a vehicle for P-MSC in a hindlimb ischemia model improved tissue cell survival, limb reperfusion, and inhibited muscular atrophy [32].

Another protein-engineered hydrogel (SHIELD family) was designed at an in situ stiffness of 200–400 Pa (SHIELD-2.5) to protect cells from shear damages during injection, but also increased cell viability in vitro. When used as a vehicle for endothelial cells from induced Pluripotent Stem Cells (iPSC-EC) treatment in a hindlimb ischemia model, the SHIELD-2.5 hydrogel improved both cell tissue-retention and arteriogenesis [34]. Another type of hydrogel that has shown recent promise in other ischemic diseases are Small-Molecule (SM) hydrogels [35], that have the advantage of being inherently biocompatible, biodegradable, and are relatively easy to design and produce [36]. Thus, Huan et al. developed a SM hydrogel via a disulfide-bond reduction method to test whether P-MSC would enhance therapeutic effects in a hindlimb ischemia model [37]. Their results suggest that their novel SM hydrogel creates an artificial niche capable of increasing stem cell survival and paracrine activity, which improved the limb reperfusion and muscle regeneration [37].

Another strategy to improve bioscaffold-based tissue engineering employs the addition of peptides into the hydrogel construct to enhance stem cell survival, engraftment, and therapeutic effects. Wang et al. capitalized on this concept by constructing a Chitosan (CS) and Hyaluronic Acid (HA) based hydrogel that was immobilized with the C domain of Insulin-like Growth Factor (IGF-1C) peptide (CS-HA-IGF-1C), to determine if this engineered hydrogel could increase cell retention and paracrine effects [38]. IGF-1C was chosen as an ideal peptide due to its known ability to hasten skeletal muscle regeneration [39], improve stem cell engraftment and its resultant neovascularization [40], and protects cells against apoptosis. Thus, the investigators tested whether their engineered bioscaffold would enhance the therapeutic effects of Adipose Derived Stem Cells (ADSC) in a hindlimb ischemia model. The CS-HA-IGF-1C hydrogel demonstrated improved ADSC survival and engraftment, which promoted limb reperfusion and muscle regeneration, which the investigators ascribe to improved paracrine actions. Thus, it becomes apparent that a promising new strategy for cell-based therapies in limb ischemia is developing delivery vehicles and bioscaffolds that enhance cell survival, paracrine effects, and ultimately improve therapeutic efficacy.
6. Increasing Cell’s Therapeutic Potential

As mentioned previously, patients with diabetes mellitus and/or critical limb ischemia are often older and thus have older, diseased stem/progenitor cell populations as well. Thus, another strategy to improve stem cell therapeutic potential is to produce stem cells that have either been rescued from their diseased state or have been genetically engineered to enhance their pro-angiogenic/pro-repair phenotype. It has been shown that diabetic patients have impaired stem/progenitor cells when compared to healthy controls [17–19]. Thus strategies to save the therapeutic potential of these impaired cells may improve current cell therapies in patient with diabetes. Lian et al. hypothesized that mitochondrial Reactive Oxygen Species (ROS) may be elevated in diabetic patients, and thus play a role in their stem cells’ dysfunctional phenotype [41]. They demonstrated that pre-treatment of diabetic ADSC (dADSC) with a mitochondrial ROS scavenger (miTEMPO) not only increased in vitro differentiation and proliferation, but also improved in vivo angiogenic capacity [41]. Capilla-Gonzalez et al., also determined that dADSC had impaired functionality, which they demonstrated was likely due to impaired Platelet-Derived Growth Factor (PDGF) signaling. Thus, they attempted to restore the dADSC to a pro-regenerative phenotype via incubation with a recombinant form of human PDGF (PDGF-BB) and found that in vitro migration and proliferation were rescued in the dADSC and in vivo cell homing to a cutaneous injury site was improved [42]. Castilla et al., also utilized Diabetic mice (Lepr\db/db) bone marrow cells and primed them via co-culture with SDF-1\alpha and then utilized these pre-treated bone marrow cells to treat a diabetic wound model [10]. These cells increased wound closure rate, neovascularization, and EPC recruitment, thus demonstrating that the diabetic phenotype, which had been previously shown to have low SDF-1\alpha levels, may be rescued from dysfunction. In addition to diabetic stem/progenitor cells having inherent dysfunction, Al Rifai et al. sought to characterize Bone Marrow Cells (BMC) from CLI patients enrolled in the Bone Marrow Autograft in Limb Ischemia (BALI) trial [43]. This trial, while efficacious in some facets of BMC therapy in CLI, did not demonstrate a difference in amputation rates between treatment groups, which is one of the main goals of cell therapies [44]. Their investigations determined that although BMC do contain MSC, they are not abundant and potentially lack pro-angiogenic capabilities. Thus, they co-cultured these MSC with an Endothelial Growth Medium (EGM)-2 and demonstrated that these Stimulated MSC (S-MSC) had improved in vitro proliferation and exhibited an increased transcriptome of vascular cell adhesion molecule-1 (VCAM1), which is an intermediary molecule that traffics interactions between stem/progenitor and endothelial cells, thereby increasing its homing capacity. In vivo, the S-MSC also demonstrated improved reperfusion in a hindlimb ischemia model and improved muscle repair [43].

Recently, another strategic therapeutic avenue is the genetic manipulation of stem cells to overexpress certain genes that may enhance angiogenic effects. This is typically achieved via vector transduction (viral or plasmid) that incorporates into the cellular DNA and results in an increased genomic expression of said gene. One such attempt by Park et al., transduced MSC via plasmid transduction to overexpress Green Fluorescent Protein (eGFP) and Vascular Endothelial Growth Factor (VEGF), they then utilized Fluorescent Activated Cell Sorting (FACS) analysis to ensure only cells expressing the target gene were included.
in the treatment. These were then transplanted into a hindlimb ischemia model where they demonstrated improved limb reperfusion, and muscle repair effects, when compared with control MSC [45]. Another approach, either via a Transcription Activator-Like Effector Nucleases (TALEN) [46] or lentiviral transduction [47], increased expression of dual chemotactic genes, granulocyte chemotactic protein-2 (GCP-2) and stromal-derived factor-1 (SDF-1α). Reports on stem cells with overexpression of both GCP-2 [48] and SDF-1α [10,49] have improved neovascularization in ischemic models. Thus, investigators sought to boost the therapeutic efficacy of MSC via overexpression of both GCP-2 and SDF-1α [46,47]. Both studies demonstrated that regardless of vector (TALEN [46] or lentiviral [47]) or stem cell type (amniotic MSC [46] or adipose MSC [47]), their utilization in a hindlimb ischemia model demonstrated improved MSC angiogenic potentials in vitro and improved limb ischemia in vivo [46,47]. While most studies have attempted to alter MSC, one study performed genetic manipulations on Endothelial Progenitor Cells (EPC) to attempt enhanced therapeutic angiogenesis. Steinle et al., developed a novel method of non-integrating cell transfection via mRNAs, which would lead to transient production of the target proteins in the cell. Specifically, the proteins VEGF-A, SDF-1α, and Angiopoietin-1 (ANG-1) were transfected via mRNAs due to their known involvement in angiogenesis [50]. In vivo, EPC transduced with ANG-1 only were found to have the strongest angiogenic potential, however in vitro data suggests that the cocktail of all three mRNAs showed significantly improved tube formation. Although this study did not include a hindlimb ischemia model, this novel mRNA vector strategy with EPC is promising.

7. Allogeneic Stem Cells from Extra Embryonic Structures

Clearly bone marrow MSC are the most abundant stem cell type utilized for both pre-clinical and clinical trials [51], however other cell types (or other extraction locations) have been shown to be effective or more-so than MSC extracted from the bone marrow. MSC have been shown to be isolated from many locations within both the adult human (autologous) or extra embryonic (allogeneic) structures. For adult tissues these include trabecular/cortical bone, periosteum, synovial membranes, adipose tissue, tendons, skeletal muscle, peripheral blood, and bone, while extra embryonic structures containing MSC include umbilical cord blood, Wharton’s jelly, placental, and chorionic tissues. Due to the procedural risk of performing a bone marrow extraction and poor cell yield requiring in vitro expansion, investigations into utilizing MSCs from other locations have become increasingly popular, especially from the extra embryonic structures such as the umbilical cord blood, placental, and Wharton’s jelly as they have been shown to have increased therapeutic potentials [52,53]. One such recent pre-clinical investigation utilized an MSC-product derived from Wharton’s jelly, CardioCell, in a hindlimb ischemia model and reported improved reperfusion and leg function compared to vehicle [54]. These results have supported the initiation of a clinical trial ongoing at the writing of this text (NO CLI-Study, EudraCT number: 2016–004684–40) [55]. Multiple pre-clinical trials have also demonstrated that Umbilical Cord (UC) MSC also induce reperfusion in ischemic models [56,57], and was recently shown to have superiority over BM-MSC in a murine hindlimb ischemia model [58], and has also shown efficacy in early trials. However, these have not yet reached Phase II/III [59]. The PACE trial (NCT-03000770) Employs Placental
Derived Adherent Stromal Cells (PLX-PAD) and is currently in Phase III as a double-blinded, placebo-controlled, randomized controlled trial. This “off the shelf” cell-based therapy has shown previous success in pre-clinical trials demonstrating pro-angiogenic, anti-inflammatory, and regenerative properties and in two small open label Phase I trials demonstrated favorable 1-year Amputation Free Survival (AFS) and improved pain-score and tissue perfusion. The aim of the ongoing trial utilizing PLX-PAD (NCT-03000770) is to evaluate AFS and also the tolerability and safety of this novel therapeutic approach [60].

8. Alternative Therapies

Although cell-base therapies have shown promise for regenerative vascular medicine, there are also concerns with their utilization. Many of these drawbacks such as poor stem/progenitor mobilization and homing, aged/diseased autologous stem cells, poor survival and engraftment, and low to modest therapeutic effects have been investigated and improved upon as this review has detailed. However, certain issues with cell therapy such as the requirement of large number of cells for therapeutic effect (thus requiring culture expansion), the potential for cancerous transformation, and possible immunologic rejection remain a concern. Thus, investigators have begun to expand both stem cell and stem-cell associated therapeutics such as utilizing induced Pluripotent Stem Cells (iPSC) and extracellular microvesicles (i.e. exosomes.) Lian et al., induced MSC differentiation from iPSCs, thus creating iMSCs. In a murine hindlimb ischemia model, the iMSC treatment was superior in both limb reperfusion and muscle regeneration when compared with control BM-MSC [61]. Similarly, exosomes from iMSCs were used as treatment in a murine hindlimb ischemia model and had higher limb reperfusion, limb salvage, and blood vessel formation [62]. Exosomes have also been successfully used for angiogenesis from ADSC [63] and have also been used alongside hydrogel delivery vehicles with improved therapeutic angiogenesis [64].

9. Conclusion

Although attempts at vascular regenerative medicine through stem cell therapies have not yet shown definitive and clinically pronounced improvement in amputation free survival in human clinical trials, many current pre-clinical and clinical trials are attempting to improve aspects of stem cell therapies that are believed to account for failure to produce the desired outcomes. Increasing therapeutic potential such as increasing stem/progenitor cell mobilization and homing, engineering stem cell to increase their inherent angiogenic potential, improving delivery vehicles to improve cell survival and paracrine effects, utilizing extra embryonic stem cells, and novel approaches using iPSCs and exosome therapies are the future of vascular regenerative medicine as new limb salvage treatments. As this review has demonstrated, many of these therapies have shown improved outcomes and many will likely be involved in future human clinical trials.

References

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, et al. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45: 5–67.
2. Nehler MR, Duval S, Diao L, Annex BH, Hiatt WR, et al. (2014) Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg 60: 686–695. [PubMed: 24820900]

3. Kalbaugh CA, Kucharska-Newton A, Wruck L, Lund JL, Selvin E, et al. (2017) Peripheral Artery Disease Prevalence and Incidence Estimated From Both Outpatient and Inpatient Settings Among Medicare Fee-for-Service Beneficiaries in the Atherosclerosis Risk in Communities (ARIC) Study. J Am Heart Assoc 6: 003796.

4. Bertele V, Roncaglioni MC, Pangrazi J, Terzian E, Tognoni EG (1999) Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group. Eur J Vasc Endovasc Surg 18: 401–410. [PubMed: 10612642]

5. Marso SP, Hiatt WR (2006) Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 47: 921–929. [PubMed: 16516072]

6. Jude EB, Oyibo SO, Chalmers N, Boulton AJ (2001) Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 24: 1433–1437. [PubMed: 11473082]

7. Hinchcliffe RJ, Forsythe RO, Apelqvist J, Boyko Ed J, Fitridge R, et al. (2019) IWGDF Guideline on diagnosis, prognosis and management of peripheral artery disease in patients with a foot ulcer and diabetes. IWGDF Guideline, Oxford, UK.

8. Qadura M, Terenzi DC, Verma S, Al-Omran M, Hess DA (2018) Concise Review: Cell Therapy for Critical Limb Ischemia: An Integrated Review of Preclinical and Clinical Studies. Stem Cells 36: 161–171. [PubMed: 29226477]

9. Parikh PP, Liu ZZ, Velazquez OC (2017) A Molecular and Clinical Review of Stem Cell Therapy in Critical Limb Ischemia. Stem Cells Int 2017: 3750829.

10. Castilla DM, Liu ZZ, Tian R, Li Y, Livingstone AS, et al. (2012) A novel autologous cell-based therapy to promote diabetic wound healing. Ann Surg 256: 560–572. [PubMed: 22964729]

11. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, et al. (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: 1–7. [PubMed: 11440969]

12. Abdul Wahid SF, Ismail NA, Wan Jamaludin WF, Muhamad NA, Abdul Hamid MKA, et al. (2018) Autologous cells derived from different sources and administered using different regimens for ‘no-option’ critical lower limb ischaemia patients. Cochrane Database Syst Rev 8: 010747.

13. Lu D, Chen B, Liang Z, Deng W, Jiang Y, et al. (2011) Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract 92: 26–36. [PubMed: 21216483]

14. Teraa M, Gremmelts H, Wijnand JGI, Verhaar MC (2018) Cell Therapy for Chronic Limb-Threatening Ischemia: Current Evidence and Future Directions. Stem Cells Transl Med 7: 842–846. [PubMed: 30070050]

15. Duscher D, Rennert RC, Januszky M, Anghel E, Maan ZN, et al. (2014) Aging disrupts cell subpopulation dynamics and diminishes the function of mesenchymal stem cells. Sci Rep 4: 7144. [PubMed: 25413454]

16. Dimmeler S, Leri A (2008) Aging and Disease as Modifiers of Efficacy of Cell Therapy. Circ Res 102: 1319–1330. [PubMed: 18535269]

17. Acosta L, Hmadcha A, Escacena N, Pérez-Camacho I, de la Cuesta A, et al. (2013) Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity. Diabetes 62: 4266–4269. [PubMed: 24043757]

18. Kim H, Han JW, Lee JY, Choi YJ, Sohn YD, et al. (2015) Diabetic Mesenchymal Stem Cells Are Ineffective for Improving Limb Ischemia Due to Their Impaired Angiogenic Capability. Cell Transplant 24: 1571–1584. [PubMed: 25008576]

19. Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, et al. (2007) Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 117: 1249–1259. [PubMed: 17476357]

20. Kwon SG, Park I, Kwon YW, Lee TW, Park GT, et al. (2019) Role of stem cell mobilization in the treatment of ischemic diseases. Arch Pharm Res 42: 224–231. [PubMed: 30680545]
21. Kwon YW, Lee SJ, Heo SC, Lee TW, Park GT, et al. (2019) Role of CXCR2 in the Ac-PGP-Induced Mobilization of Circulating Angiogenic Cells and its Therapeutic Implications. Stem Cells Transl Med 8 : 236–246. [PubMed: 30474937]

22. Braber S, Koelink PJ, Henricks PA, Jackson PL, Nijkamp FP, et al. (2011) Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. Am J Physiol Lung Cell Mol Physiol 300: 255–265.

23. Kwon YW, Heo SC, Lee TW, Park GT, Yoon JW, et al. (2017) N-Acetylated Proline-Glycine-Proline Accelerates Cutaneous Wound Healing and Neovascularization by Human Endothelial Progenitor Cells. Sci Rep 7: 43057. [PubMed: 28230162]

24. Zhang J, Li Y, Li H, Zhu B, Wang L, et al. (2018) GDF11 Improves Angiogenic Function of EPCs in Diabetic Limb Ischemia. Diabetes 67: 2084–2095. [PubMed: 30026260]

25. Mei W, Xiang G, Li Y, Li H, Xiang L, et al. (2016) GDF11 Protects against Endothelial Injury and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Null Mice. Mol Ther 24: 1926–1938. [PubMed: 27502608]

26. Hong HS, Lee J, Lee E, Kwon YS, Lee E, et al. (2009) A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nat Med 15: 425–435. [PubMed: 19270709]

27. Amadesi S, Reni C, Katare R, Meloni M, Oikawa A, et al. (2012) Role for substance p-based nociceptive signaling in progenitor cell activation and angiogenesis during ischemia in mice and in human subjects. Circulation 125: 1774–1786. [PubMed: 22392530]

28. Park HJ, Kuai R, Jeon EJ, Seo Y, Jung Y, et al. (2018) High-density lipoprotein-mimicking nanodiscs carrying peptide for enhanced therapeutic angiogenesis in diabetic hindlimb ischemia. Biomaterials 161: 69–80. [PubMed: 29421564]

29. Liu ZJ, Tian R, An W, Zhuge Y, Li Y, et al. (2010) Identification of E-selectin as a novel target for the regulation of postnatal neovascularization: implications for diabetic wound healing. Ann Surg 252: 625–634. [PubMed: 20881769]

30. Liu ZJ, Tian R, Li Y, Zhang L, Shao H, et al. (2016) SDF-1α-induced dual pairs of E-selectin/ligand mediate endothelial progenitor cell homing to critical ischemia. Sci Rep 6: 34416. [PubMed: 27713493]

31. Liu ZJ, Daftarian P, Kovalski L, Wang B, Tian R, et al. (2016) Directing and Potentiating Stem Cell-Mediated Angiogenesis and Tissue Repair by Cell Surface E-Selectin Coating. PLoS One 11: 0154053.

32. Wang R, Yao X, Li T, Li X, Jin M, et al. (2019) Reversible Thermoresponsive Hydrogel Fabricated from Natural Biopolymer for the Improvement of Critical Limb Ischemia by Controlling Release of Stem Cells. Adv Healthc Mater 8: 1900967.

33. Spiliopoulos S, Theodosiadou V, Barampoutis N, Katsanos K, Davelouras P, et al. (2017) Multi-center feasibility study of microwave radiometry thermometry for non-invasive differential diagnosis of arterial disease in diabetic patients with suspected critical limb ischemia. J Diabetes Complications 31: 1109–1114. [PubMed: 28479156]

34. Foster AA, Dewi RE, Cai L, Hou L, Strassberg Z, et al. (2018) Protein-engineered hydrogels enhance the survival of induced pluripotent stem cell-derived endothelial cells for treatment of peripheral arterial disease. Biomater Sci 6: 614–622. [PubMed: 29406542]

35. Wu Z, Chen G, Zhang J, Hua Y, Li J, et al. (2017) Treatment of Myocardial Infarction with Gene-modified Mesenchymal Stem Cells in a Small Molecular Hydrogel. Sci Rep 7: 15826. [PubMed: 29158523]

36. Miao X, Cao W, Zheng W, Wang J, Zhang X, et al. (2013) Switchable catalytic activity: selenium-containing peptides with redox-controllable self-assembly properties. Angew Chem Int Ed Engl 52: 7781–7785. [PubMed: 23784972]

37. Huang A, Liu D, Qi X, Yue Z, Cao H, et al. (2019) Self-assembled GFFYK peptide hydrogel enhances the therapeutic efficacy of mesenchymal stem cells in a mouse hindlimb ischemia model. Acta Biomater 85: 94–105. [PubMed: 3050934]

38. Wang X, Zhang J, Cui W, Fang Y, Li L, et al. (2018) Composite Hydrogel Modified by IGF-1C Domain Improves Stem Cell Therapy for Limb Ischemia. ACS appl mater interfaces 10: 4481–4493. [PubMed: 29327586]

HSOA J Stem Cells Res Dev Ther. Author manuscript; available in PMC 2022 February 10.
39. Borselli C, Storrie H, Benesch-Lee F, Shvartsman D, Cezar C, et al. (2010) Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc Natl Acad Sci U S A 107: 3287–3292. [PubMed: 19966309]

40. Enoki C, Otani H, Sato D, Okada T, Hattori R, et al. (2010) Enhanced mesenchymal cell engraftment by IGF-1 improves left ventricular function in rats undergoing myocardial infarction. Int J Cardiol 138: 9–18. [PubMed: 19411121]

41. Lian K, Wang Q, Zhao S, Yang M, Chen G, et al. (2019) Pretreatment of Diabetic Adipose-derived Stem Cells with mitoTEMPO Reverses their Defective Proangiogenic Function in Diabetic Mice with Critical Limb Ischemia. Cell Transplant 28: 1652–1663. [PubMed: 31684763]

42. Capilla-Gonzalez V, Lopez-Beas J, Escacena N, Aguilera Y, de la Cuesta A, et al. (2018) PDGF Restores the Defective Phenotype of Adipose-Derived Mesenchymal Stromal Cells from Diabetic Patients. Mol Ther 26: 2696–2709. [PubMed: 30195725]

43. Al-Rifai R, Nguyen P, Bouland N, Terryn C, Kanagaratnam L, et al. (2019) In vivo efficacy of endothelial growth medium stimulated mesenchymal stem cells derived from patients with critical limb ischemia. J Transl Med 17: 261. [PubMed: 31399109]

44. Pignon B, Sevestre MA, Kanagaratnam L, Pernod G, Stephan D, et al. (2017) Autologous Bone Marrow Mononuclear Cell Implantation and Its Impact on the Outcome of Patients With Critical Limb Ischemia - Results of a Randomized, Double-Blind, Placebo-Controlled Trial. Circ J 81: 1713–1720. [PubMed: 28603176]

45. Park JS, Bae SH, Jung S, Lee M, Choi D (2019) Enrichment of vascular endothelial growth factor secreting mesenchymal stromal cells enhances therapeutic angiogenesis in a mouse model of hindlimb ischemia. Cytotherapy 21: 433–443. [PubMed: 30879964]

46. Jeong IS, Park Y, Ryu HA, An HS, Han JH, et al. (2018) Dual chemotactic factors-secreting human amniotic mesenchymal stem cells via TALEN-mediated gene editing enhanced angiogenesis. Int J Cardiol 260: 156–162. [PubMed: 29506937]

47. Min Y, Han S, Aae Ryu H, Kim SW (2018) Human adipose mesenchymal stem cells overexpressing dual chemotactic gene showed enhanced angiogenic capacity in ischaemic hindlimb model. Cardiovasc Res 114: 1400–1409. [PubMed: 29659744]

48. Kim SW, Lee DW, Yu LH, Zhang HZ, Kim CE, et al. (2012) Mesenchymal stem cells overexpressing GCP-2 improve heart function through enhanced angiogenic properties in a myocardial infarction model. Cardiovasc Res 95: 495–506. [PubMed: 22886775]

49. Tang J, Wang J, Yang J, Kong X, Zheng F, et al. (2009) Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Eur J Cardiothorac Surg 36: 644–650. [PubMed: 19524448]

50. Steinle H, Golombek S, Behring A, Schlensak C, Wendel HP, et al. (2018) Improving the Angiogenic Potential of EPCs via Engineering with Synthetic Modified mRNAs. Mol Ther Nucleic Acids 13: 387–398. [PubMed: 30343252]

51. Lopes L, Setia O, Aurshina A, Liu S, Hu H, et al. (2018) Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research. Stem Cell Res Ther 9: 188. [PubMed: 29996912]

52. Barlow S, Brooke G, Chatterjee K, Price G, Pelekanos R, et al. (2008) Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 17: 1095–1107. [PubMed: 19006451]

53. Blumberg SN, Berger A, Hwang L, Pastar I, Warren SM, et al. (2012) The role of stem cells in the treatment of diabetic foot ulcers. Diabetes Res Clin Pract 96: 1–9. [PubMed: 22142631]

54. Musial-Wysocka A, Kot M, Sulkowski M, Majka M (2019) Regenerative Potential of the Product “CardioCell” Derived from the Wharton’s Jelly Mesenchymal Stem Cells for Treating Hindlimb Ischemia. Int J Mol Sci 20: 4632.

55. https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004684-40/PL.

56. Pereira AR, Mendes TF, Ministro A, Teixeira M, Filipe M, et al. (2016) Therapeutic angiogenesis induced by human umbilical cord tissue-derived mesenchymal stromal cells in a murine model of hindlimb ischemia. Stem Cell Res Ther 7: 145. [PubMed: 27680210]

57. Yin C, Liang Y, Zhang J, Ruan G, Li Z, et al. (2016) Umbilical Cord-Derived Mesenchymal Stem Cells Relieve Hindlimb Ischemia through Enhancing Angiogenesis in Tree Shrews. Stem Cells Int 9742034.
58. Wang Z, Zheng L, Lian C, Qi Y, Li W, et al. (2019) Human Umbilical Cord-Derived Mesenchymal Stem Cells Relieve Hindlimb Ischemia by Promoting Angiogenesis in Mice. Stem Cells Dev 28: 1384–1397. [PubMed: 31407635]

59. Can A, Celikkan FT, Cinar O (2017) Umbilical cord mesenchymal stromal cell transplantations: A systemic analysis of clinical trials. Cytoteraphy 19: 1351–1382. [PubMed: 28964742]

60. Norgren L, Weiss N, Nikol S, Hinchliffe RJ, Lantis JC, et al. (2019) PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial. Eur J Vasc Endovasc Surg 57: 538–545. [PubMed: 30686676]

61. Lian Q, Zhang Y, Zhang J, Zhang HK, Wu X, et al. (2010) Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 121: 1113–1123. [PubMed: 20176987]

62. Hu G-w, Li Q, Niu X, Hu B, Liu J, et al. (2015) Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice. Stem Cell Res Ther 6: 10. [PubMed: 26268554]

63. Figliolini F, Ranghino A, Grange C, Cedrino M, Tapparo M, et al. (2019) Extracellular Vesicles From Adipose Stem Cells Prevent Muscle Damage and Inflammation in a Mouse Model of Hindlimb Ischemia: Role of Neuregulin-1. Arterioscler Thromb Vasc Biol 40: 239–254. [PubMed: 31665908]

64. Zhang K, Zhao X, Chen X, Wei Y, Du W, et al. (2018) Enhanced Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes with an Injectable Hydrogel for Hindlimb Ischemia Treatment. ACS ACS Appl Mater Interfaces 10: 30081–30091. [PubMed: 30118197]
Figure 1:
Schematic of various strategies employed in recent years to improve upon endogenous or exogenous stem cell’s inherent therapeutic potential for the treatment of limb ischemia.
### Table 1:
Summary of strategies to increase stem cell therapeutic potentials in critical limb ischemia.

| Cell-Type | Methodology | Author |
|-----------|-------------|--------|
| **Mobilization and Tissue Homing** | | |
| Progenitor cells (Sca1+Flk1+ cells) | IM injections of Ac-PGP | Kwon et al. [23] |
| EPCs | IP injections of rGDF11 | Zhang et al. [24] |
| MSCs, EPCs | IV injection of HDL-SP nanodiscs | Park et al. [28] |
| MSC | IV injection of Ac-G5-sE-sel nanocarrier coated MSC | Liu et al. [31] |
| **Improved Delivery Methods** | | |
| P-MSC | Thermoresponsive MC-based hydrogel | Wang et al. [32] |
| iPSC-EC | SHIELD-2.5 hydrogel | Foster et al. [34] |
| P-MSC | SM-Hydrogel | Huang et al. [37] |
| ADSC | CS-HA-IGF-1C hydrogel | Wang et al. [38] |
| **Increasing Cell’s Inherent Angiogenic Potential** | | |
| dADSC | In vitro co-culture of cells with mTEmPO | Lian et al. [41] |
| dADSC | In vitro co-culture of cells with PDGF-BB | Capilla-Gonzalez et al. [42] |
| dBMDSC | In vitro co-culture of cells with SDF-1α | Castilla et al. [10] |
| BM-MSC | In vitro co-culture of cells with EGM-2 | Al Rifai [43] |
| BM-MSC | Ex vivo VEGF plasmid transduction | Park et al. [45] |
| AM-MSC | Ex vivo GCP-2 and SDF-1α TALEN transduction | Jeong et al. [46] |
| ADSC | Ex vivo GCP-2 and SDF-1α lentiviral transduction | Min et al. [47] |
| EPC | Ex vivo mRNA transduction of pro-angiogenic proteins | Steinle et al. [50] |
| **Allogeneic Stem Cells from Extra embryonic Sources** | | |
| CardioCell | CardioCell as treatment in HLI model | Musial-Wysocka et al. [54] |
| UC-MSC | UC-MSC as treatment in HLI models | Pereira et al. [56] |
| PLX-PAD | Phase III trial as treatment for CLI (NCT-03006770) | Norgren et al. [60] |
| **Alternative Therapies** | | |
| iPSC | Creation of MSC from iPSCs and utilizing them as treatment in HLI model | Lian et al. [61] |
| iPSC exosomes | iPSC exosomes as treatment in HLI model | Hu et al. [62] |
| ADSC exosomes | ADSC exosomes as treatment in HLI model | Figliolini et al. [63] |
| ADSC exosomes | ADSC exosomes coupled with hydrogel delivery method | Zhang et al. [64] |

IM: Intramuscular; IP: Intraperitoneal; IV: Intravenous; MSC: Mesenchymal Stem Cells, P-MSC: Placental- MSC; BM-MSC: Bone Marrow derived MSC; UC-MSC: Umbilical Cord derived MSC; AM-MSC: Amniotic derived MSC; P-MSC: Placental MSC; ADSC: Adipose-Derived Stromal Cells; iPSC: induced Pluripotent Stem Cell; EC: Endothelial Cell; dADSC: diabetic ADSC; dBMDSC: diabetic Bone Marrow Derived Stem Cells; Ac-PGP: N-acetyl proline-glycine-proline; rGDF11: recombinant Growth Differentiation Factor-11; HDL-SP: High-Density Lipoprotein-Substance P; Ac-G5-sE-sel: Acetylated-G5 dendrimers associated with E-selectin; MC: Methyl Cellulose; SM: Small Molecule; CS-HA-IGF-1C: Chitosan, Hyaluronic Acid insulin-like growth factor 1C; PDGF-BB: recombinant Platelet-Derived Growth Factor, SDF-1α: Stromal-Derived Factor-1; EGM-2: Endothelial Growth Medium-2; VEGF: Vascular Endothelial Growth Factor; GCP-2: Granulocyte Chemotactic Protein-2, TALEN: Transcription Activator-Like Effector Nucleases, HLI: Hindlimb Ischemia, CLI: Critical Limb Ischemia, iPSC: MSC induced from iPSC.